5-phenyl-thiophene-2-carboxylic acid amide | 62404-14-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-phenyl-thiophene-2-carboxylic acid amide
• 英文别名: 5-Phenyl-thiophen-2-carbonsaeure-amid；5-Phenylthiophene-2-carboxamide
• CAS: 62404-14-2
• 化学式: C₁₁H₉NOS
• mdl: MFCD12922938
• 分子量: 203.265
• InChiKey: OYSOOLCZEMWVQN-UHFFFAOYSA-N

物化性质

• 沸点：
  377.0±30.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5t-phenyl-2-thioxo-pent-4-enoic acid 在 乙醇 、 碘 作用下， 生成 5-phenyl-thiophene-2-carboxylic acid amide
  参考文献：
  名称：

  Preparation and Absorption Spectra of Some β-Aryl-α-Mercaptoacrylic Acids and Related Disulfides^1,2

  摘要：

  DOI：

  10.1021/jo01107a006

文献信息

• New Piperazine Compound and Use Thereof as a HCV Polymerase Inhibitor
  申请人：Abe Hiroyuki

  公开号：US20080081818A1

  公开（公告）日：2008-04-03

  The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由以下式[I]表示的化合物，其中每个符号如规范中定义，或其药学上可接受的盐，或其溶剂化合物，以及含有该化合物的抗HCV剂和HCV聚合酶抑制剂。本发明的化合物基于HCV聚合酶抑制活性显示出抗HCV活性，并且可用作预防或治疗丙型肝炎的药剂。
• [EN] INHIBITORS OF PSEUDOMONAS AERUGINOSA LECB<br/>[FR] INHIBITEURS DE PSEUDOMONAS AERUGINOSA LECB
  申请人：HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH

  公开号：WO2016151066A1

  公开（公告）日：2016-09-29

  The present invention relates to compounds derived from deoxy fucose. These compounds are useful as lectin inhibitors, especially as inhibitors of LecB. The invention also relates to pharmaceutical compositions comprising these compounds. The invention further relates to therapeutic uses of these compounds, especially to the prophylaxis or treatment of infections involving Pseudomonas aeruginosa.

  本发明涉及源自脱氧呋喃糖的化合物。这些化合物可作为凝集素抑制剂，特别是作为LecB的抑制剂。该发明还涉及包含这些化合物的药物组合物。此外，该发明还涉及这些化合物的治疗用途，特别是用于预防或治疗涉及铜绿假单胞菌感染的情况。
• [EN] IMIDAZOLYL BIPHENYL IMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS<br/>[FR] IMIDAZOLYLE DIPHÉNYLE IMIDAZOLES INHIBITRICES DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009102325A1

  公开（公告）日：2009-08-20

  The present disclosure relates to compounds Formule (I), compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in. the treatment of HCV infection.

  本公开涉及化合物式（I），组合物以及用于治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这种化合物的药物组合物以及使用这些化合物治疗HCV感染的方法。
• SUBSTITUTED PYRIMIDINYLPYRROLOPYRIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
  申请人：Marchionni Chiara

  公开号：US20120178770A1

  公开（公告）日：2012-07-12

  Pyrimidinylpyrrolopyridinone derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  本发明公开了式（I）中定义的嘧啶基吡咯吡啶酮衍生物及其药学上可接受的盐，以及制备它们的方法和包含它们的制药组合物；该发明的化合物可能在治疗与蛋白激酶活性失调有关的疾病，如癌症中有用。
• NEW PIPERAZINE COMPOUND AND USE THEREOF AS A HCV POLYMERASE INHIBITOR
  申请人：Abe Hiroyuki

  公开号：US20120107273A1

  公开（公告）日：2012-05-03

  The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种由下式[I]表示的化合物，其中每个符号如规范所定义，或其药学上可接受的盐，或其溶剂化物，以及含有该化合物的抗HCV剂和HCV聚合酶抑制剂。本发明的化合物基于HCV聚合酶抑制活性表现出抗HCV活性，可作为预防或治疗丙型肝炎的药剂。